Overview
SwiftPharma pioneers sustainable, scalable, and affordable plant-made therapeutic proteins including vaccines, antibodies, cytokines, and enzymes. The company uses plants as individual bioreactors to produce high-value, animal-free proteins that redefine safety and sustainability, supporting innovation from proof of concept through production and facility development.
In the news
- The future of recombinant proteins is taking root. SwiftPharma’s new website is live! Discover how we’re putting plants to work to produce recombinant proteins for life sciences and cosmetic industry. 🔬 New possibilities - Shared ambitions - It starts here! 🤝 🎬 Watch the preview. 👉 Explore the website and tell us your needs: www.swiftpharma.eu #SwiftPharma #RecombinantProteins #Biotechnology #LifeThroughLeaves
- You can’t have sustainable local manufacturing of health products without research, development, and innovation. Yesterday, SwiftPharma had the pleasure of welcoming a delegation of representatives from Medicines Patent Pool, Africa CDC, #Kenya, #Senegal, and #Uganda as part of the #Belgian Health R&D Study Tour. The visit offered an opportunity to exchange perspectives on how innovation, sustained investment, and cross-border collaboration can strengthen local health manufacturing capacity in #Africa. Our Founder & CSO, Jeroen
- One last Japan post from our recent trade mission, I promise! 😉 But these visits deserve a place in the recap. 📍 At Nakanoshima Qross in Osaka, we had the opportunity to present SwiftPharma’s vision and ambitions to a representative of the Osaka Prefectural Government and the Nakanoshima Qross board.🔬 Our visits to Osaka Life Science Nexus (O-Nexus) and VMaCS, the Value Chain Consortium for Mass Cell Production, were particularly impressive. Seeing research, entrepreneurship and cell manufacturing come together
- Asia offers exciting opportunities for European HealthTech companies, but there’s no one-size-fits-all approach. Our Founder & CSO, Jeroen Hofenk, will join an expert panel at #HIS2026 in Bruges on 1 December to discuss market-entry strategies, partnerships, opportunities and challenges across Asia. Looking forward to sharing insights and connecting with fellow innovators! Save the date! 01 December, 2026 (16:45–18:00) #SwiftPharma #HealthTech #Biotech #Internationalization #PlantBased #Biomanufacturing
- Asia isn't one market, your market-entry strategy shouldn't be either. Asia offers huge opportunities for European healthtech companies, but knowing where to start is a different story. Different healthcare systems, different regulations, different reimbursement models, different geopolitical realities... What works in Singapore may not work in China, Japan, South Korea or Southeast Asia. So how do you find the right entry point for sustainable growth? 💡 At #HIS2026, we're bringing together ecosystem leaders, industry experts,
- Two days at BioJapan. Valuable connections and new opportunities for SwiftPharma. Our recent visit to BioJapan at PACIFICO Yokohama was a valuable opportunity to introduce SwiftPharma to the Japanese market and connect with people from across the global life sciences industry. 🤝 Through many productive meetings, we gained insights into market needs, explored potential collaborations and discussed how our plant-based biomanufacturing platform could support future partners. Bringing together people from different countries and
- Building connections between Europe and Japan—and new opportunities for SwiftPharma. It was a privilege to present at the EU-Japan Biotech & Pharma Partnering Conference in Osaka, bringing together companies, research institutions and clusters from both regions. Co-organised by the Osaka Prefecture - Business and Investment, the EU-Japan Centre for Industrial Cooperation and the Enterprise Europe Network, with support from bioclusters, embassies and trade organisations, the event showed a shared commitment to
- Back from Japan. It was again a great experience thanks to #FIT (@MidoriSato, Asami Torimitsu, Els Verhulst), my fellow colleagues from #SwiftPharma (@VincentJaenen), #RodeKruis (@PietJamaels), other flemish companies, @TaishiKusumoto, and our Japanese friends/customers. I also had to pitch for the first time our patient-specific SBDD platform, where instead of recombinant proteins, we are targeting proteins isolated from primary cells to get closer to the true native state (disease specific ptms, proteolysis, aggregation). I
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.